Literature DB >> 17874061

[Inductive systemic therapy of urological tumors with curative intent].

F vom Dorp1, S Krege, H Rübben.   

Abstract

Up to now systemic therapy with curative intent is possible in only a few tumors. Concerning advanced malignant tumors in urology only testicular cancer can be cured. In metastatic urothelial cancer of the bladder this might be possible in single cases. In advanced renal cell carcinoma a recent group of new substances, so-called target-specific substances, have gained attention. In several phase III studies with sunitinib, sorafenib, and temsirolimus at least progression-free survival could be clearly prolonged. The amazing results in testicular cancer were possible by consistent performance of clinical trials. The success in treatment also is an example for interdisciplinarity. Especially in advanced stages treatment consists of two components, chemotherapy, correctly performed concerning dose and interval, followed by complete residual tumor resection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17874061     DOI: 10.1007/s00120-007-1539-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  22 in total

1.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

2.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.

Authors:  R de Wit; G Stoter; S B Kaye; D T Sleijfer; W G Jones; W W ten Bokkel Huinink; L A Rea; L Collette; R Sylvester
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

5.  Noncancer causes of death in survivors of testicular cancer.

Authors:  Sophie D Fosså; Ethel Gilbert; Graça M Dores; Jinbo Chen; Katherine A McGlynn; Sara Schonfeld; Hans Storm; Per Hall; Eric Holowaty; Aage Andersen; Heikki Joensuu; Michael Andersson; Magnus Kaijser; Mary Gospodarowicz; Randi Cohen; Eero Pukkala; Lois B Travis
Journal:  J Natl Cancer Inst       Date:  2007-04-04       Impact factor: 13.506

6.  Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.

Authors:  Alexandra W van den Belt-Dusebout; Janine Nuver; Ronald de Wit; Jourik A Gietema; Wim W ten Bokkel Huinink; Patrick T R Rodrigus; Erik C Schimmel; Berthe M P Aleman; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2006-01-20       Impact factor: 44.544

7.  Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial.

Authors:  Jean-Pierre Droz; Andrew Kramar; Pierre Biron; José-Luis Pico; Pierre Kerbrat; Jean Pény; Hervé Curé; Christine Chevreau; Christine Théodore; Jeannine Bouzy; Stéphane Culine
Journal:  Eur Urol       Date:  2006-10-27       Impact factor: 20.096

8.  Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?

Authors:  Paul Sweeney; Randall Millikan; Machelle Donat; Christopher G Wood; Arlene Siefker Radtke; Curtis A Pettaway; H Barton Grossman; Colin P N Dinney; David A Swanson; Louis L Pisters
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

9.  Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.

Authors:  Anja Lorch; Christian Kollmannsberger; Joerg Thomas Hartmann; Bernd Metzner; Ingo G H Schmidt-Wolf; Wolfgang E Berdel; Florian Weissinger; Jan Schleicher; Gerlinde Egerer; Antje Haas; Rebekka Schirren; Jörg Beyer; Carsten Bokemeyer; Oliver Rick
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

10.  Fertility, gonadal and sexual function in survivors of testicular cancer.

Authors:  R A Huddart; A Norman; C Moynihan; A Horwich; C Parker; E Nicholls; D P Dearnaley
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

View more
  1 in total

1.  [Systemic therapy of renal cell carcinoma].

Authors:  M Staehler; C Tüllmann; P Nuhn; N Haseke; C G Stief
Journal:  Urologe A       Date:  2010-12       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.